Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758594 | 1.00 | HTR1A (0.41) | HTR1AL3MBTL1PLGALDH1A1POLB | |
| SCHEMBL5758589 | 1.00 | HTR1A (0.41) | HTR1AL3MBTL1PLGALDH1A1POLB | |
| SCHEMBL5758273 | 0.88 | HTR1A (0.43) | HTR1APLGSLC6A4 | |
| SCHEMBL5756274 | 0.88 | HTR1A (0.43) | HTR1APLGSLC6A4 | |
| SCHEMBL5756271 | 0.88 | HTR1A (0.43) | HTR1APLGSLC6A4 | |
| SCHEMBL5759705 | 0.86 | CA2 (0.38) | HTR1APLGSLC6A4 | |
| SCHEMBL5759707 | 0.86 | CA2 (0.38) | HTR1APLGSLC6A4 | |
| SCHEMBL5856322 | 0.86 | CA2 (0.38) | HTR1APLGSLC6A4 | |
| SCHEMBL5756057 | 0.86 | HTR1A (0.45) | HTR1APLG | |
| SCHEMBL5758860 | 0.86 | HTR1A (0.45) | HTR1APLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | HTR1A 4/4885L3MBTL1 3780/4885PLG 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.